GMAB May 2024 50.000 call
| Previous Close | 0.2000 |
| Open | 0.2000 |
| Bid | 0.0000 |
| Ask | 5.0000 |
| Strike | 50.00 |
| Expire Date | 2024-05-17 |
| Day's Range | 0.2000 - 0.2000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 3 |
Business WireGenmab Completes Acquisition of ProfoundBio
COPENHAGEN, Denmark, May 21, 2024--Genmab A/S (Nasdaq: GMAB) announced today that it has completed its acquisition of ProfoundBio, Inc., a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADC)s and ADC technologies for the treatment of cancers in an all-cash transaction of USD 1.8 billion (subject to adjustment for ProfoundBio’s closing net debt and transaction expenses).
GlobeNewswireTransactions in Connection with Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; May 21, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from May 13, 2024 to May 17, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcement
Business WireGenmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
COPENHAGEN, Denmark, May 14, 2024--Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, will be presented at the 2024 European Hematology Association (EHA) Congress, being held in Madrid, Spain and virtually, June 13-16, 2024.
